Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)
Status:
Completed
Trial end date:
2005-11-16
Target enrollment:
Participant gender:
Summary
This was a single center, open-label, two-way crossover, drug-drug-interaction study to
determine the effect of multiple dosing of omeprazole on 4 consecutive days on the
pharmacokinetics of a single dose of an immediate-release capsule of CG5503 (tapentadol) in
healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Grünenthal GmbH
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.